Back to Browse Journals » Research Reports in Clinical Cardiology » Volume 4

Galectin-3: clinical utility and prognostic value in patients with heart failure

Authors Kramer F

Published Date February 2013 Volume 2013:4 Pages 13—22

DOI http://dx.doi.org/10.2147/RRCC.S28562

Received 6 December 2012, Accepted 3 January 2013, Published 7 February 2013

Frank Kramer

Clinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, Germany

Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.

Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read: